在COVID-19中评估狄克洛芬雅的风险:减轻不良结果的策略
Chia Siang Kow1,2, Dinesh Sangarran Ramachandram3, Syed Shahzad Hasan2
1School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia.
Inflammopharmacology
|November 27, 2024
概括
在COVID-19期间使用迪克洛菲纳克可能会因为氧化应激和心血管风险而恶化结果. 药剂师对于管理这些风险和引导患者选择更安全的NSAID替代品至关重要.
科学领域:
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
- 心脏病学 心脏病学
背景情况:
- 非类固醇抗炎药物 (NSAIDs),特别是迪克洛菲纳克,在COVID-19大流行期间引发了安全问题.
- 迪克洛芬雅克的机制,包括产生活性氧物种 (ROS),可能会加剧COVID-19的超炎症状态.
- COVID-19 患者面临心血管事件和肝脏功能障碍的风险增加,这些情况可能会因狄克洛芬雅而恶化.
研究的目的:
- 为了评估在COVID-19患者中使用迪克洛芬雅克的风险.
- 突出药剂师在减轻NSAID不良影响方面的重要作用.
- 在疫情期间促进更安全的NSAID选择和患者教育.
主要方法:
- 评论评价现有文献在COVID-19的背景下对迪克洛芬雅克的风险.
- 对狄克洛芬雅克的药理性质的分析,包括氧化应激和心血管影响.
- 审查药剂师在药物管理,患者咨询和药物监督中的作用.
主要成果:
- 狄克洛菲纳克诱导氧化应激和线粒体功能障碍的能力可能会加剧COVID-19炎症.
- 与狄克洛菲纳克相关的心血管风险增加 (心肌梗塞,中风) 对COVID-19患者尤其令人担忧.
- 狄克洛菲纳克的肝毒性带来额外的风险,特别是在患有先前存在的或COVID-19相关的肝脏问题的患者中.
结论:
- 药剂师在识别高风险患者和引导他们转向更安全的NSAIDs,如ibuprofen或naproxen时至关重要.
- 有效的患者教育迪克洛芬雅克的副作用和促进NSAID替代品对于患者的安全至关重要.
- 药剂师参与药物监测和个性化药物管理可以优化NSAID在COVID-19和其他炎症状况中的使用.
更多相关视频
09:03Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic
Published on: November 7, 2020
4.7K
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
440
相关概念视频
01:21Rheumatic Heart Disease III: Medical Management
3
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
3
01:22Myocarditis IV: Nursing Management
2
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
2
01:14Myocarditis III: Medical Management
2
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
2
01:19Pharmacovigilance
773
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
773
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
121
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
121